STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR S.

Business Wire • Feb 23, 2026

STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years

STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.

Zacks Investment Research • Feb 19, 2026

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing.

Business Wire • Feb 17, 2026

Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 3, 2026

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the “Board”) has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work t.

Business Wire • Feb 2, 2026

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

STAAR Surgical Company (NASDAQ: STAA) shares are down on Thursday as the company is undergoing significant board changes.

Benzinga • Jan 15, 2026

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates (“Broadwood”), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5% of ST.

Business Wire • Jan 15, 2026

Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing

STAAR Surgical said on Tuesday it plans to terminate its merger agreement with Swiss eyecare giant Alcon after failing to secure enough shareholder votes to approve the deal, sending its shares down more than 12%.

Reuters • Jan 6, 2026

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates by STAAR's proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held today. STAAR intends to terminate its merger agreement with Alcon. No terminat.

Business Wire • Jan 6, 2026

STAAR Surgical Merger With Alcon Fails After Shareholders Vote No

STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of Stockholders.

Benzinga • Jan 6, 2026